Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
| Data | Nome del titolare | Azioni transazionate | Intervallo di valore ($) | Tipo di transazione | Intervallo di prezzo ($) | Azioni a fine dichiarazione | % di variazione |
|---|---|---|---|---|---|---|---|
| 2026-06-10 | Ms. Jennifer RileyChief Strategy Officer | -588,00 | 7,70k | Sale to Issuer | 13,10 | 5,50k | -9,66% |
| 2026-06-10 | Mr. Paul C. VarkiChief Legal Officer | -1,08k | 14,16k | Sale to Issuer | 13,10 | 8,28k | -11,55% |
| 2026-06-10 | Mr. Christopher Ryan SullivanCFO & Head of Investor relations | -138,00 | 1,81k | Sale to Issuer | 13,10 | 873,00 | -13,65% |
| 2026-06-10 | Dr. Mittie DoyleChief Medical Officer | -1,08k | 14,20k | Sale to Issuer | 13,10 | 8,28k | -11,58% |
| 2026-05-28 | Dr. Mittie DoyleChief Medical Officer | -679,00 | 5,40k | Derivative Exercise and Sale | 8,04 - 16,00 | 3,62k | - |
| 2026-05-15 | Dr. Mittie DoyleChief Medical Officer | -3,00k | 18,33k | Derivative Exercise and Sale | 12,65 - 18,76 | 3,62k | - |
| 2026-05-07 | Mr. Christopher Ryan SullivanCFO & Head of Investor relations | -18,61k | 264,99k | Derivative Exercise and Sale | 9,88 - 24,12 | 423,00 | - |
| 2026-05-06 | Mr. Paul C. VarkiChief Legal Officer | -75,06k | 573,29k | Derivative Exercise and Sale | 8,04 - 23,71 | 3,63k | - |
| 2026-05-06 | Mr. Christopher Ryan SullivanCFO & Head of Investor relations | -47,00k | 570,84k | Derivative Exercise and Sale | 8,04 - 22,57 | 423,00 | - |
| 2026-05-05 | Dr. Mittie DoyleChief Medical Officer | -108,23k | 996,41k | Derivative Exercise and Sale | 8,04 - 22,88 | 3,62k | - |
| 2026-05-06 | Mr. Mitchell ChanInsider | -3,17k | 72,46k | Automatic Disposition | 22,88 | 3,17k | -50,01% |
| 2026-04-29 | Mr. Christopher Ryan SullivanCFO & Head of Investor relations | -16,92k | 222,59k | Automatic Disposition | 13,09 - 13,23 | 423,00 | -97,56% |
| 2026-04-06 | Dr. Mittie DoyleChief Medical Officer | -3,97k | 21,29k | Derivative Exercise and Sale | 12,65 - 18,01 | 3,62k | - |
| 2026-04-01 | Mr. Christopher Ryan SullivanCFO & Head of Investor relations | -15,96k | 270,59k | Automatic Disposition | 15,86 - 17,57 | 17,34k | -47,93% |
| 2026-04-01 | Dr. Mittie DoyleChief Medical Officer | -679,00 | 5,40k | Derivative Exercise and Sale | 8,04 - 16,00 | 3,62k | - |
| 2026-03-28 | Ms. Samantha Scollard TruexIndependent Director | 3,17k | 0,00 | Derivative Exercise and Retained Stock | - | 6,33k | 99,97% |
| 2026-03-28 | Mr. Aaron KantoffIndependent Director | 3,17k | 0,00 | Derivative Exercise and Retained Stock | - | 6,33k | 99,97% |
| 2026-03-28 | Dr. Gilla KaplanIndependent Director | 3,17k | 0,00 | Derivative Exercise and Retained Stock | - | 6,33k | 99,97% |
| 2026-03-28 | Dr. Garry A. NeilPresident, CEO & Director | 42,97k | 0,00 | Derivative Exercise and Retained Stock | - | 90,11k | 91,16% |
| 2026-03-28 | Dr. Garry A. NeilPresident, CEO & Director | -21,89k | 304,08k | Derivative Exercise and Sale | 13,89 | 90,11k | - |
| 2026-03-28 | Mr. Christopher Ryan SullivanCFO & Head of Investor relations | 15,96k | 0,00 | Derivative Exercise and Retained Stock | - | 33,30k | 92,05% |
| 2026-03-28 | Mr. Christopher Ryan SullivanCFO & Head of Investor relations | -8,24k | 114,47k | Derivative Exercise and Sale | 13,89 | 33,30k | - |
| 2026-03-28 | Mr. Mitchell ChanInsider | 3,17k | 0,00 | Derivative Exercise and Retained Stock | - | 6,33k | 99,97% |
| 2026-03-28 | Dr. Jonathan GoldmanInsider | 3,17k | 0,00 | Derivative Exercise and Retained Stock | - | 3,17k | - |
| 2026-03-16 | Dr. Mittie DoyleChief Medical Officer | -25,49k | 116,76k | Derivative Exercise and Sale | 8,04 - 16,15 | 3,62k | - |
| 2025-12-10 | Dr. Mittie DoyleChief Medical Officer | -1,01k | 4,15k | Sale to Issuer | 4,10 | 3,62k | -21,86% |
| 2025-12-10 | Mr. Paul C. VarkiChief Legal Officer | -1,02k | 4,17k | Sale to Issuer | 4,10 | 3,63k | -21,85% |
| 2025-12-10 | Ms. Jennifer RileyChief Strategy Officer | -637,00 | 2,61k | Sale to Issuer | 4,10 | 2,66k | -19,35% |
| 2025-12-10 | Mr. Christopher Ryan SullivanCFO & Head of Investor relations | -155,00 | 635,50 | Sale to Issuer | 4,10 | 17,34k | -0,89% |
| 2025-11-14 | Dr. Jonathan GoldmanInsider | -8,20k | 36,63k | Derivative Exercise and Sale | 9,88 - 14,35 | 0,00 | - |
| 2025-11-14 | Dr. Jonathan GoldmanInsider | -3,17k | 45,29k | Vendita | 14,30 | 0,00 | -100,00% |
Assistenza: support@advfn.it
Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni
Registrati con e-mail
Hai già un account? Accedi
Non hai un account? Registrati
Registrandomi, confermo di aver letto, capito, e accetto i termini e condizioni ADVFN e che sono un investitore privato.
Caratteristiche principali
Premium
